Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Primary Membranoproliferative Glomerulonephritis
NCT02093533Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Mar 2014
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in membranoproliferative glomerulonephritis (MPGN), sponsored by Mario Negri Institute for Pharmacological Research. Started Mar 2014; status: completed.
02
Drugs
eculizumab
03
Conditions
membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on NCT02093533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093533.